Chinese medical and pharmaceutical-focused venture fund Bioventure Investment Management Ltd. has led an undisclosed series A+ round in Ark Biosciences, a Shanghai-based drug developer targeting respiratory viruses, influenza and Hepatitis B.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?